2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2073 Real-world efficacy of luspatercept in myelodysplastic neoplasms with elevated baseline serum erythropoietin (EPO ≥ 500 U/L).

Qingyan Gao, Tiejun Qin, MD2, Zefeng Xu, MD3, Jinying Zhao4, Shiqiang Qu5, Meng Jiao6, Gang Huang, MD7, Zhijian Xiao8, Bing Li, MD9
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 MD Anderson Mays Cancer Center at UT Health San Antonio, San Antonio, United States
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Luspatercept is currently a preferred therapeutic agent for anemia in patients with myelodysplastic neoplasms (MDS), particularly in those with an serum erythropoietin (sEPO) level of < 500 U/L or the presence of a SF3B1 mutation. However, therapeutic options are limited for MDS anemia patients with sEPO levels ≥500 U/L. This study evaluated the real-world efficacy of luspatercept in treating patients with MDS who have elevated sEPO levels (>500 IU/L). 

Methods: A retrospective analysis was conducted on clinical data from MDS patients treated at the Blood Disease Hospital, Chinese Academy of Medical Sciences, between August 2022 and December 2025, who received continuous luspatercept therapy for at least two cycles (6 weeks) and had a pre-treatment serum EPO level ≥500 IU/L. 

Results: A total of 58 patients were included, comprising 14 (24.1%) newly diagnosed and 44 (75.9%) relapsed/refractory cases. The median baseline hemoglobin level was 6 g/dL (range, 4.1-10.2). The median initial dose of luspatercept was 1.11 mg/kg body weight (range, 0.93–1.30). According to the hematological response (HR) definition used in the luspatercept COMMANDS phase III trial—defined as sustained red blood cell transfusion independence for at least 12 weeks with a mean hemoglobin increase of at least 1.5g/dL—the overall HR rate was 34.5% (20/58), with a median duration of response (MDOR) of 12 months (range, 3-37). Among newly diagnosed patients, HR was 28.6% (4/14) with an MDOR of 15.5 months (range: 6–36); among relapsed/refractory patients, HR was 36.4% (16/44) with an MDOR of 12 months (range, 3-37). For the MDS-SF3B1 subtype, HR was 39.4% (13/33) with an MDOR of 15 months (range, 4-37). Median follow-up was 13 months (range, 2-45), and median overall survival had not been reached. Univariate analysis showed that IPSS-R score, IPSS-M score, baseline hemoglobin, SF3B1 mutation status, ring sideroblasts ≥5%, number of gene mutations, and disease duration were not predictive factors for treatment response. However, patients in the low-risk IPSS-M group had the longest MDOR at 26 months (range, 13–36), while those with ring sideroblasts ≥5% had an MDOR of 15 months (range, 8–36), significantly longer than those with <5% ring sideroblasts [4 (range, 3–31) months, P=0.004]. 

Conclusion: Luspatercept remains effective in MDS patients with serum EPO levels ≥500 IU/L, and patients in the low-risk IPSS-M group or those with ring sideroblasts ≥5% tend to have longer response durations.

Bing Li, MD: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China - Research Funding